Juan Perez-Ruixo, PhD, PharmD

Senior Director, EU Pharmacometric Group Lead, Clinical Pharmacology & Pharmacometrics
Janssen Research & Development, LLC, a Johnson & Johnson Company

Poster(s):

• 047: How Much PK Data Do We Really Need in Phase 3? A Milvexian Case Study
  Sunday, September 8, 2024

  5:00 PM – 7:00 PM ET

• 149: Milvexian Does Not Prolong the QTc Interval: A Thorough QT Study in Healthy Subjects
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET